{"entity":{"id":"mark-litzow","kind":"person","name":"Mark R. Litzow","aka":[],"tldr":"Leukaemia specialist who led E1910, the trial that put blinatumomab into frontline treatment for adults in remission.","summary":"Mark Litzow is Professor of Medicine at Mayo Clinic, Chair of the ECOG-ACRIN Leukemia Committee and Study Chair of E1910. A haematologist specialising in acute lymphoblastic leukaemia, immunotherapy and transplant, he chaired ECOG-ACRIN E1910, the trial that put blinatumomab consolidation into frontline treatment for adults in MRD-negative remission and led to a 2024 label change. His papers report blinatumomab for MRD-negative acute lymphoblastic leukaemia in adults in the New England Journal of Medicine and allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukaemia in Blood. His work centres on CD19 and CD3 directed therapy in B-ALL.","asOf":"2026-09-08","links":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litzow%20MR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mark%20R.%20Litzow"}],"tags":[],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":["cd19","cd3"],"drugs":["blinatumomab"],"companies":["ecog-acrin"],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":["e1910"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medicine, Mayo Clinic; Chair, ECOG-ACRIN Leukemia Committee; Study Chair, E1910","institutionId":"mayo-clinic","specialisms":["Acute lymphoblastic leukaemia","Immunotherapy","Transplant"],"profiles":[{"label":"Mayo Clinic research faculty","url":"https://www.mayo.edu/research/faculty"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Litzow%20MR%5BAuthor%5D"},{"label":"Google Scholar","url":"https://scholar.google.com/scholar?q=Mark%20R.%20Litzow"}],"papers":[{"title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","journal":"New England Journal of Medicine","year":2024,"url":"https://doi.org/10.1056/NEJMoa2312948","doi":"10.1056/NEJMoa2312948"},{"title":"Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia","journal":"Blood","year":2010,"url":"https://doi.org/10.1182/blood-2009-10-249128","doi":"10.1182/blood-2009-10-249128"}]},"route":"/people/mark-litzow/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"},{"id":"cd3","kind":"target","name":"CD3","route":"/targets/cd3/"}],"drug":[{"id":"blinatumomab","kind":"drug","name":"Blinatumomab","route":"/drugs/blinatumomab/"}],"company":[{"id":"ecog-acrin","kind":"company","name":"ECOG-ACRIN Cancer Research Group","route":"/companies/ecog-acrin/"}],"institution":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"}],"trial":[{"id":"e1910","kind":"trial","name":"ECOG-ACRIN E1910","route":"/trials/e1910/"}],"paper":[{"id":"paper-e1910-blinatumomab-mrd-negative-all-nejm-2024","kind":"paper","name":"ECOG-ACRIN E1910: adding blinatumomab to chemotherapy for adults with B-cell ALL already in MRD-negative remission","route":"/key-papers/paper-e1910-blinatumomab-mrd-negative-all-nejm-2024/"}]}}